ArticleProtein science : a publication of the Protein Society2025
An asymmetric tetrabody is a potent and efficacious agonist of the erythropoietin receptor in vitro and in vivo.
Jarrett J Adams, Levi L Blazer, Jacky Chung, Minoo Karimi, Taylor Davidson, Heather A Bruce, Alexander U Singer, Ning Yang, Lia Cardarelli, Isabelle Pot and 6 more
Article in Protein science : a publication of the Protein Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Levi L BlazerAnvil Institute for Systems Biologics, Canada.
Jacky ChungAnvil Institute for Systems Biologics, Canada.
Minoo KarimiUniversité de Montréal, Canada.
Taylor DavidsonUniversity of Texas Southwestern Medical Center, USA.
Heather A BruceAnvil Institute for Systems Biologics, Canada.
Alexander U SingerAnvil Institute for Systems Biologics, Canada.
Ning YangAnvil Institute for Systems Biologics, Canada.
Lia CardarelliAnvil Institute for Systems Biologics, Canada.
Isabelle PotAnvil Institute for Systems Biologics, Canada.
Luigi ColomboEPOK Therapeutics, Canada.
Lily Jun-Shen HuangUniversity of Texas Southwestern Medical Center, USA.
Yue MaUniversity of Texas Southwestern Medical Center, USA.
Stephen W MichnickUniversité de Montréal, Canada.
Orson W MoeEPOK Therapeutics, Canada.
Sachdev S SidhuAnvil Institute for Systems Biologics, Canada.
Funding
JAK2 signaling in erythropoiesisR01HL089966 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI LILY JUNSHEN HUANG · 2007 to 2026
$7.4M
Pathogenesis of Uric Acid Nephrolithiasis: The Multifaceted Role of Renal LipidsR01DK081423 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI MAALOUF, NAIM M, MOE, ORSON W · 2009 to 2023
$6.1M
Impact of Dietary Phosphate Excess on Exercise Capacity and Visceral AdiposityR01HL159994 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI Jarett D Berry, WANPEN VONGPATANASIN · 2022 to 2026
$4.0M
Origin of Excess Acid in Uric Acid UrolithiasisR01DK115703 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI BROWNING, JEFFREY D, MOE, ORSON W · 2019 to 2023
$2.2M
Lymphatics and lymphangiogenesis in kidney function and inflammationR01DK119497 · NIDDK · TEXAS A&M UNIVERSITY · PI RUTKOWSKI, JOSEPH MICHAEL · 2020 to 2024
$2.1M
The Relation of Soluble Klotho with Cardiovascular Disease, Chronic Kidney Disease Progression, and Blood Pressure in the Systolic Blood Pressure Intervention TrialR01DK128208 · NIDDK · TUFTS MEDICAL CENTER · PI DREW, DAVID ALAN, NEYRA, JAVIER A. · 2021 to 2025
$1.6M
Canada Foundation for Innovation IOF-33363Canadian Cancer Society Research Institute 704757CIHR PJT-159640NHLBI NIH HHS R01 HL089966NHLBI NIH HHS R01 HL159994NIDDK NIH HHS R01 DK081423NIDDK NIH HHS R01 DK115703NIDDK NIH HHS R01 DK119497NIDDK NIH HHS R01 DK128208NIH HHS R01 DK081423NIH HHS R01 DK115703NIH HHS R01 DK128208NIH HHS R01 HL089966NIH HHS R01 HL159994
6 · The paper itself
Abstract
Erythropoietin (EPO) initiates EPO receptor (EPOR) signaling in hematopoietic cells by binding to an asymmetric EPOR dimer through two different sites. We engineered dimeric diabody-Fc (Db-Fc) fusion proteins that appeared to act as potent agonists of human EPOR in cell proliferation assays. However, detailed analysis of their oligomeric forms revealed that the predominant Db-Fc species bound EPOR with high affinity but failed to induce cell proliferation. Instead, a minor oligomeric form, identified as a putative tetrabody (Tb) fused to two Fc domains (Tb-Fc
Indexed as
Receptors, ErythropoietinAnimalsCell ProliferationCrystallography, X-RayErythropoietinHumansImmunoglobulin Fc FragmentsMiceModels, MolecularRecombinant Fusion ProteinsErythropoietinImmunoglobulin Fc FragmentsReceptors, ErythropoietinRecombinant Fusion Proteinsagonistanemiaantibodydiabodydimerdrug designEPOEPORerythropoiesiserythropoiesis‐stimulating agentprotein engineeringtetrabody
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
An asymmetric tetrabody is a potent and efficacious agonist of the erythropoietin receptor in vitro and in vivo. · full record | OpenQuestion